Core Viewpoint - Goldman Sachs initiates coverage of Connora-B (02162) with a "Buy" rating and a target price of HKD 92.67, highlighting the potential of its first commercial product, Stapokibart, in various therapeutic areas [1] Group 1: Product Overview - Stapokibart has received approval in mainland China for atopic dermatitis, chronic sinusitis, and seasonal allergic rhinitis indications, establishing a first-mover advantage for the company [1] - The peak sales for Stapokibart are expected to exceed RMB 5 billion by 2035, providing a solid valuation foundation for the company [1] Group 2: Future Growth Potential - Greater growth momentum is anticipated from CM512, which is believed to be a superior option for asthma and chronic obstructive pulmonary disease [1] - Global sales for CM512 are projected to reach USD 3.3 billion before the point of sale (PoS) stage and USD 694 million after the PoS stage by 2035 [1]
高盛：首予康诺亚-B买入评级 目标价92.67港元